胎盘植入患者胎盘间充质干细胞外泌体来源的Apoa1蛋白调控EndMT介导子痫前期大鼠胎盘血管新生的机制研究

子痫前期（PE）是一种胎盘血管新生受限的疾病，其治疗手段有限。而胎盘植入是一种血管过度增生的疾病，但其血管增生能力是否可改善PE结局尚属未知。前期课题组发现:胎盘植入患者的胎盘间充质干细胞（PA-hPMSCs）具有更强的促血管新生能力，且其外泌体是发挥功能的关键成分。进一步Itraq蛋白组学分析显示Apoa1是PA-hPMSCs与其外泌体差异最显著的蛋白。同时课题组也发现PE大鼠胎盘组织内EndMT转化明显增加。而文献表明Apoa1可调控EMT/EndMT的转化。但PA-hPMSCs外泌体富含的Apoa1蛋白是否通过调控PE胎盘EndMT过程来影响血管新生是未知的。因此在本研究中，课题组拟通过利用CRISPA/Cas9，SRμCT，免疫荧光共定位等技术进行深入研究，阐明PA-hPMSCs外泌体来源的Apoa1-EndMT过程在PE中的具体机制，为临床治疗PE提供新的思路。

Preeclampsia (PE) is a pregnancy disease with restricted placental angiogenesis, and its treatment options are limited. Placenta accreta is a disease of hyperproliferation of blood vessels, but whether the ability of angiogenesis can improve the outcome of PE is still unknown. In the previous study, we found that placental mesenchymal stem cells (PA-hPMSCs) of patients with placental implantation have stronger angiogenesis ability, and the exosomes derived from PA-hPMSCs play the key role in the process of angiogenesis. Further Itraq proteomics analysis showed that Apoa1 is the most significant protein between PA-hPMSCs and its exosomes. Meanwhile, our team found that the EndMT transformation process in the placenta tissue of PE rats was significantly increased. The literature shows that Apoa1 can regulate the conversion process of EMT/EndMT. However, it is unknown whether the Apoa1 protein derived from exosomes of PA-hPMSCs affects angiogenesis by regulating the EndMT process of the placenta in preeclampsia. Therefore, in this study, we intends to use CRISPA/Cas9 technology, SRμCT, immunofluorescence co-localization and other methods to clarify the specific functions and mechanism of the Apoa1-EndMT process derived from PA-hPMSCs exosomes in PE. Then we hope to provides new ideas for the clinical treatment of PE.